Mode
Text Size
Log in / Sign up

Case report and literature review of thymoma associated with stiff person syndrome and myasthenia gravis

Case report and literature review of thymoma associated with stiff person syndrome and myasthenia gr…
Photo by Europeana / Unsplash
Key Takeaway
Recognize the potential for thymoma-associated stiff person syndrome and myasthenia gravis to present as an overlap syndrome.

This publication consists of a case report of a 55-year and a literature review of 7 additional patients. The authors explore the clinical and genomic characteristics of thymoma-associated stiff person syndrome and myasthenia gravis, focusing on the intersection of thymic epithelial neoplasia, impaired inhibitory neurotransmission, and neuromuscular junction autoimmunity.

In the index case, the patient showed substantial clinical improvement following thymectomy, immunotherapy, and symptomatic agents. A review of 7 additional patients from the literature suggested that these cases are typically characterized by GAD65 positivity and WHO B1/B2 mixed histology. These patients also demonstrated favorable outcomes after combined immunotherapy and surgical resection.

Genomic analysis via whole-exome sequencing of the resected thymoma in the index case revealed a somatic CACNA1A frameshift variant and variants in immune-signaling genes. This analysis showed an enrichment of pathways related to calcium channels, GABAergic synapses, and immune regulation.

The authors note significant limitations, as the primary evidence is based on a single index case supplemented by a small literature review. Furthermore, the genomic findings are derived from exploratory sequencing of a single resected tissue. Clinicians should recognize this overlap syndrome as a rare but potentially identifiable clinical entity.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
BackgroundThymoma is frequently associated with myasthenia gravis (MG), but the coexisting of stiff person syndrome (SPS) is exceedingly rare. This overlap syndrome poses diagnostic and therapeutic challenges, and its immunopathogenic basis is not well understood.MethodsA 55-year-old woman with thymoma-associated SPS and MG was evaluated using detailed clinical, electrophysiological, serological and radiologic investigations. In addition, a PubMed-based literature review of published cases of thymoma complicated by SPS with MG was conducted. Exploratory whole-exome sequencing (WES) with pathway analysis were performed on resected thymoma tissue.ResultsThe index patient presented with progressive gait unsteadiness, painful axial and lower-limb stiffness, dysarthria and dysphagia. Examination revealed marked truncal rigidity and exaggerated startle responses. Serology demonstrated high-titer anti–glutamic acid decarboxylase 65 (GAD65) and elevated acetylcholine receptor (AChR) antibodies. Chest computed tomography (CT) demonstrated an anterior mediastinal soft-tissue mass highly suggestive of thymoma. Treatment with immunotherapy, symptomatic agents and thymectomy resulted in substantial clinical improvement. The literature search identified seven additional patients with thymoma-associated SPS and MG, typically characterized by GAD65 positivity, World Health Organization (WHO) B1/B2 mixed histology, and favorable outcomes after combined immunotherapy and surgical resection. WES of the thymoma revealed a somatic CACNA1A frameshift variant and variants in immune-signaling genes, with enrichment of pathways related to calcium channels, γ-aminobutyric acidergic (GABAergic) synapses and immune regulation.ConclusionThymoma-associated SPS and MG constitute a rare but recognizable overlap syndrome. Integration of clinical, literature and exploratory genomic data supports a convergent mechanism involving thymic epithelial neoplasia, impaired inhibitory neurotransmission and neuromuscular junction autoimmunity.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.